Orange Book Blog

CPhI "Pharma IPR India 2012" Conference, Mumbai, January 31 to February 2, 2012

CPhI Conferences will hold a three-day conference on pharmaceutical intellectual property in Mumbai, India, from January 31, 2012 to February 2, 2012.  The first day of the conference will focus on India; the second day will focus on the United States; and the third day will focus on the rest of the world, including Europe, Japan and emerging markets.  I have the honor of speaking on the Hatch-Waxman Act on Day 2.

The complete agenda is as follows:

Day 1: India

• Patent Scenario in India
• Patentability in the Pharmaceutical Industry
• Section 3(d) of the Indian Patent Act
• Data Exclusivity
• Compulsory Licensing
• Patent Oppotions in India--Current Trends
• Trademarks and Copyrights

Day 2: United States

• The United States Patent System
• The Hatch-Waxman Act
• Paragraph IV Certifications
• The America Invents Act
• Biosimilars in the United States
• Freedom to Operate in the United States
• Doctrine of Equivalents
• Polymorphs

Day 3: Europe, Japan and Emerging Markets

• Patent Systems in Europe, Japan and Emerging Markets
• Supplementary Protection Certificates
• Biosimilars in Europe
• Freedom to Operate in the EU
• Doctrine of Equivalents in the EU
• Japanese Patent System

For more information or to register, please visit the conference website.

ACI "Advanced Forum on Biotech Patents" Conference, Boston, Nov. 30 - Dec. 1

American Conference Institute will be holding its 13th Advanced Forum on Biotech Patents conference at the Omni Parker House hotel in Boston, MA, November 30th to December 1st.  ACI subtitles this conference, "practical strategies for prosecuting and litigating biotech patents in a rapidly shifting legal environment."

The agenda includes many presentations that will prove valuable:

• Protection vs. Exploitation: Preparing for the Next Chapter in the Development of Biosimilars
• Examining the Potential Effect of Patent Reform on PTO Practices and its Impact on Biotech Patents
• Preparing for a Radical Overhaul of the U.S. Patent System: The Impact of Reform on Biotech Patent Strategies
• Examining 35 U.S.C. 101 Subject Matter Patentability in the Wake of Myriad and Prometheus
• Microsoft v. i4i and Stanford v. Roche: Understanding Their Collective Implications for the Biotechnology Industry
• Confronting the Written Description Requirement Post-Centocor and Evaluating its Impact on Biotech Patent Practices
• The Emergence of the New Obviousness Standard and its Impact on Biotech Patenting: Taking a Closer Look at Obviousness-Type Double Patenting
• Inequitable Conduct Following Therasense: Assessing its Significance for Biotech Patent Litigation
• International Filing: Strategic Considerations and Advanced Tactics for Patenting Biotech Inventions Abroad
• Analyzing and Resolving the Difficulties of Claiming Joint Infringement After Akamai and McKesson
• Creating Favorable Patent Tactics in Developing Countries

In addition, ACI is offering an option pre-conference session in the morning of November 30th that will feature two Supervisory Patent Examiners from teh USPTO:  "Integrating Changes at the PTO into Biotech Patent Practices."  ACI is also offering optional post-conference Master Class on December 2nd:  "Successful and Practical Strategies for Patenting Antibodies."

For more information or to register, please visit the conference website.  To receive a $200 discount on registration fees, use discount code OBB 200.